Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~8 mi. ('s-Hertogenbosch, Netherlands, +206 more cities)

Jeroen Bosch Ziekenhuis

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

~8 mi. ('s-Hertogenbosch, Netherlands, +54 more cities)

Jeroen Bosch Ziekenhuis

Colorectal Carcinoma

bevacizumab, +6 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~19 mi. (Eindhoven, Netherlands, +226 more cities)

Catharina Ziekenhuis ( Site 0472)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

~19 mi. (Eindhoven, Netherlands, +43 more cities)

Catharina Hospital

Prostate Carcinoma

HC-1119

hormone therapy

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~21 mi. (Het Bosch, Netherlands, +184 more cities)

Jeroen Bosch Hospital

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~30 mi. (Breda, Netherlands, +93 more cities)

Amphia Hospital Location Molengracht ( Site 1912)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

~30 mi. (Breda, Netherlands, +209 more cities)

Amphia Ziekenhuis

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC

~39 mi. (Nijmegen, Netherlands, +35 more cities)

Novartis Investigative Site

FOLH1 Expression

Prostate Adenocarcinoma

androgen receptor-directed therapy, +2 more drugs

hormone therapy, +2 more types

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

~39 mi. (Nijmegen, Netherlands, +165 more cities)

Radboud Universitair Medisch Centrum /ID# 218948

del(11)(q10), +27 more biomarkers

Myelofibrosis

navitoclax, +1 more drug

targeted therapy

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

~39 mi. (Nijmegen, Netherlands, +41 more cities)

Novartis Investigative Site

Prostate Adenocarcinoma

lutetium Lu 177 vipivotide tetraxetan

radiation therapy, +1 more type

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~39 mi. (Nijmegen, Netherlands, +120 more cities)

Canisius-Wilhelmina Hospital

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

~39 mi. (Nijmegen, Netherlands, +88 more cities)

Radboud University Medical Center

FGFR2 Fusion

Intrahepatic Cholangiocarcinoma

futibatinib

targeted therapy